SEVOFLURANE市场的应用、分销管道和地区

预计 2025 年全球SEVOFLURANE市场规模为 4.011 亿美元，到 2032 年将达到 5.495 亿美元，2025 年至 2032 年的复合年增长率为 4.6%。

数字。 2025年SEVOFLURANE各地区市场占有率（%）

SEVOFLURANE是一种气味甜美、不易燃、高度氟化的甲基异丙基醚，用作诱导和维持全身麻醉的吸入麻醉剂。它是继DESFLURANE之后作用速度第二快的挥发性麻醉剂。

市场动态

市场上的公司正专注于引进有助于透过吸入器输送麻醉的新技术，这可能会在预测期内促进全球SEVOFLURANE市场的成长。例如，2022年4月，全球医疗技术领导者GE医疗集团宣布，其Aisys CS2麻醉输送系统上用于全身麻醉输送的Endotide（Et）控制软体已获得美国食品药物管理局（FDA）的上市前核准（PMA）。在美国，GE医疗集团是唯一核准可提供终点浓度控制全身麻醉的製造商。

预计需要麻醉的整容手术的增加将推动全球SEVOFLURANE市场的成长。例如，2022年4月，世界领先的脸部和身体整形及医疗保健协会——美国美容整形学会（Aesthetic Society）发布了其年度《美容整形外科统计数据》，报告显示，得益于使用该学会新的、更精确的数字技术获取的数据，美国2021年的整形外科手术数量有所增加。数据显示，脸部、胸部和身体的整形手术数量大幅增加。自 2020 年以来，腹部整形术、臀部增大术和抽脂术在美国的受欢迎程度都激增了 63%。隆乳、隆乳/乳房提升和乳房提升/缩小手术的数量均增加了 48%。

预计在预测期内，吸入麻醉剂重复使用技术的持续推出将推动成长。例如，2020 年 7 月，无菌药品生产和供应领域的全球领导者百特国际 (Baxter International) 宣布与医疗技术公司 Zeosys Medical 达成最终协议，将捕获和再利用麻醉气体的技术商业化。根据协议，百特将获得该技术在欧洲以外地区的独家全球销售和商业化权利，以及收购 ZeoSys Medical 的独家选择权。

本研究的主要特点

• 本研究报告对全球SEVOFLURANE市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模。
• 它揭示了不同领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、区域前景以及主要参与者采用的竞争策略的重要见解。
• 全球SEVOFLURANE市场的主要企业根据公司概况、业绩、产品系列、地理位置、分销策略、关键发展和策略以及未来计划等参数进行分析。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、技术改进、市场扩张和行销策略做出明智的决策。
• 全球SEVOFLURANE市场报告迎合了该行业的各个相关人员，例如投资者、供应商、製造商、经销商、新进入者和金融分析师。
• 相关人员可以透过用于分析全球SEVOFLURANE市场的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场概述

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 市场机会
• 影响分析
• 波特分析
• 产业趋势
• 主要亮点
• 流行病学
• 赎回方案
• 监管情景
• 产品发布和核准
• 收购与合作场景

4. 全球SEVOFLURANE市场-冠状病毒（COVID-19）大流行的影响

• COVID-19流行病学
• COVID-19 对SEVOFLURANE需求和供应的影响
• COVID-19 如何影响整个医疗保健产业

5. 2020 年至 2031 年全球SEVOFLURANE市场（依应用）

• 介绍
• 维持

6. 2020 年至 2031 年全球SEVOFLURANE市场（依通路划分）

• 医院药房
• 零售药局
• 网路药局

7. 2020 年至 2031 年全球SEVOFLURANE市场（按地区）

• 北美洲
• 美国
• 加拿大
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第八章 竞争态势

• 公司简介
  • Abbott Laboratories
  • Baxter
  • Piramal Pharma Solutions
  • Manus Aktteva Biopharma LLP
  • Maruishi Pharmaceutical Co.,Ltd.
  • Lunan Pharmaceutical Group
  • Abbvie
  • Wellona Pharma
  • Rewine Pharmaceutical
  • Troikaa Pharmaceuticals Limited

第九章分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map

第 10 章 章节

• 参考
• 调查方法

Global Sevoflurane Market is estimated to be valued at USD 401.1 Mn in 2025 and is expected to reach USD 549.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 4.6% from 2025 to 2032.

Figure. Sevoflurane Market Share (%), By Region 2025

Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether that is used as an inhalational anesthetic for general anesthesia induction and maintenance. It is the fastest-acting volatile anesthetic after desflurane.

Market Dynamics

Market players are focused on launching new technology to help delivery of anesthesia through inhalers, this could contribute to the growth of the global sevoflurane market over the forecast period. For instance, in April 2022, GE Healthcare, a leading global medical technology company, announced that its end-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System has received pre-market approval (PMA) from the U.S. Food and Drug Administration (FDA). In the U.S., GE Healthcare is the only manufacturer approved to provide general anesthesia with end-tidal concentration control.

Increasing number of aesthetic surgeries requiring anesthesia, is expected to drive the growth of global sevoflurane market. For instance, in April 2022, The Aesthetic Society, world's leading association dedicated solely to facial and body aesthetic plastic surgery and cosmetic medicine issued its annual Aesthetic Plastic Surgery Statistics, which revealed that aesthetic plastic surgery increased in 2021 in U.S. owing to data acquired using the Society's new, more accurate digital technology. The data shows a large growth in procedures for the face, breasts, and body. Abdominoplasty, buttock augmentation, and liposuction have all seen a 63% surge in popularity since 2020 in U.S. Breast augmentation, augmentation/breast lift, and breast lift/reduction treatments all increased by 48%.

Increasing launches of technology to recycle inhaled anesthetics is expected to fuel the growth over forecast period. For instance, in July 2020, Baxter International Inc., a global leader in the production and delivery of sterile medications, announced a formal agreement with ZeoSys Medical, a medical technology company, to commercialize technology to capture and recycle anesthetic gases. Baxter will have worldwide distribution rights and an exclusive license to commercialize the technology outside of Europe, as well as an exclusive option to acquire ZeoSys Medical, under the terms of the agreement.

Key features of the study:

• This report provides an in-depth analysis of global sevoflurane market, provides market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global sevoflurane market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Abbott Laboratories, Baxter, Piramal Pharma Solutions, Manus Aktteva Biopharma LLP, Maruishi Pharmaceutical Co.,Ltd., Lunan Pharmaceutical Group, Abbvie, Wellona Pharma, Rewine Pharmaceutical, and Troikaa Pharmaceuticals Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global sevoflurane market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global sevoflurane market.

Detailed Segmentation:

• Global Sevoflurane Market, By Application:
  • Induction
  • Maintenance
• Global Sevoflurane Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Sevoflurane Market, By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Abbott Laboratories
  • Baxter
  • Piramal Pharma Solutions
  • Manus Aktteva Biopharma LLP
  • Maruishi Pharmaceutical Co.,Ltd.
  • Lunan Pharmaceutical Group
  • Abbvie
  • Wellona Pharma
  • Rewine Pharmaceutical
  • Troikaa Pharmaceuticals Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Application
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Porter's Analysis
• Industry Trends
• Key Highlights
• Epidemiology
• Reimbursement Scenario
• Regulatory Scenario
• Product Launch and Approvals
• Acquisition and Collaboration Scenario

4. Global Sevoflurane Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Impact of COVID-19 on demand and supply of sevoflurane
• Impact of COVID-19 on the overall healthcare sector

5. Global Sevoflurane Market, By Application, 2020-2031 (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020-2031
  • Segment Trends
• Induction
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2031, (US$ Million)
• Maintenance
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2031, (US$ Million)

6. Global Sevoflurane Market, By Distribution Channel, 2020-2031 (US$ Million)

• Introduction
  • Market Share Analysis, 2025 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020-2031
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2031, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2031, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2031, (US$ Million)

7. Global Sevoflurane Market, By Region, 2020-2031 (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
• North America
  • Market Size and Forecast, By Application, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2031 (US$ Mn)
• U.S.
• Canada
• Latin America
  • Market Size and Forecast, By Application, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2031 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Application, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2031 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Application, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2031 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Application, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Country, 2020-2031 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Application, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2020-2031 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2020-2031 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

• Company Profiles
  • Abbott Laboratories*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Baxter
  • Piramal Pharma Solutions
  • Manus Aktteva Biopharma LLP
  • Maruishi Pharmaceutical Co.,Ltd.
  • Lunan Pharmaceutical Group
  • Abbvie
  • Wellona Pharma
  • Rewine Pharmaceutical
  • Troikaa Pharmaceuticals Limited

9. Analyst Recommendation

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

10. Section

• References
• Research Methodology
• About Us and Sales Contact